Evidence map›Paper›PMID 36419002›Full record

ArticleBMC primary care2022

International Delphi-based consensus on the appropriate use and effect of Benzydamine hydrochloride in the treatment of sore throat.

Desiderio Passali, Veronica Barat, Olga Cadevall, Hugo Miguel Freire, Ignazio Grattagliano, Ioan Gutu, Ralph Mösges, Andrey Pavlysh

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC primary care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Comparative Effects of Flurbiprofen and Benzydamine on COX-2/PGEInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Frontiers in cell and developmental biology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Desiderio PassaliInternational Federation ORL Societies (IFOS) Executive Board members, Rome, Italy. d.passali@virgilio.it.
Veronica BaratAOU Città della Salute e della Scienza di Torino, Regina Margherita Children's Hospital, Turin, Italy.
Olga CadevallClínica Rotger, Quirónsalud, Palma de Mallorca, Spain.
Hugo Miguel FreireSociedade Portuguesa de Farmacêuticos dos Cuidados de Saúde, Coimbra, Portugal.
Ignazio GrattaglianoItalian College of General Practitioners and Primary Care, Florence, Italy.
Ioan GutuGeneral Practitioner, Vaslui, Romania.
Ralph MösgesInstitute of Medical Statistics, and Computational Biology (IMSB), Medical Faculty, University at Cologne, Cologne, Germany.
Andrey PavlyshNorth-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia.
Clinica Rotger · ESNorth-Western State Medical University named after I.I. Mechnikov · RUOspedale Regina Margherita · ITSociedade Portuguesa de Cardiologia · PTSocietà Italiana di Medicina Generale · ITUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBenzydamine hydrochloride is a locally-acting Non-Steroidal Anti-Inflammatory Drug (NSAID) with combined local anesthetic and analgesic properties, indicated for the symptomatic relief of pain in acute sore throat. The aim of this study was to obtain an European Consensus among pharmacists, general practitioners and pediatricians on the appropriate use of benzydamine hydrochloride in the treatment of sore throat.

methodsThe authors developed a Delphi questionnaire organized into 15 statements focused on 4 topics: the mechanism of action of benzydamine, the benzydamine treatment in an adult patient and in a pediatric patient, and the advantages of benzydamine over other topical treatments. The survey was administered to a panel of to 320 participants including general practitioners, pediatricians, and pharmacists from 6 European countries (Italy, Germany, Portugal, Romania, Russia, and Spain), who rated their level of agreement or disagreement with each statement on a 6-point Likert scale. Consensus was predefined as more than 66% of the panel agreeing/disagreeing with each statement.

resultsPanelists' agreement on statements was very high. Consensus was reached for all 15 statements in the Delphi survey, with more than 98% positive agreement on topic 4, suggesting a shared view among European healthcare professionals (HCPs) about the advantages of benzydamine over other topical treatments. A strong consensus (> 99%) was reached for all the statements of topic 1 regarding the mechanism of action of benzydamine, except for its anesthetic properties (79%). Strong agreement was reached for all statements in topics 2 and 3 regarding the treatment of acute sore throat symptoms in the adult and pediatric patient, except for one on the efficacy of benzydamine in preventing post-operative sore throat, for which it was 67%.

conclusionBecause all relevant publications on benzydamine are dated and there are no recommendations on its use for the symptomatic treatment of sore throat in European guidelines, this Delphi-based international consensus may be important in reinforcing the appropriate use and effect of benzydamine in the treatment of sore throat among health care professionals.

Indexed as

BenzydamineGeneral PractitionersPharyngitisAdultChildHumansPainBenzydamineBenzydamineDelphi-based consensusGeneral practitionerOropharynxPharmacistsSore throatSymptomatic treatment of acute sore throat

Identifiers

PMID36419002
PMCPMC9685970
OpenAlexW4309884137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.